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Abstract
Background: A phytotherapic compound containing Pimpinella anisum L., Foeniculum vulgare Miller, Sambucus nigra L., 
and Cassia augustifolia is largely used in Brazil for the treatment of constipation. However, the laxative efficacy of the 
compound has never been tested in a randomized clinical trial. The aim of this study was to evaluate the efficacy and 
safety of the product.
Methods: This randomized, crossover, placebo-controlled, single-blinded trial included 20 patients presenting with 
chronic constipation according to the criteria of the American Association of Gastroenterology. The order of treatments 
was counterbalanced across subjects: half of the subjects received the phytotherapic compound for a 5-day period, 
whereas the other half received placebo for the same period. Both treatment periods were separated by a 9-day 
washout period followed by the reverse treatment for another 5-day period. The primary endpoint was colonic transit 
time (CTT), measured radiologically. Secondary endpoints included number of evacuations per day, perception of 
bowel function, adverse effects, and quality of life.
Results: Mean CTT assessed by X ray was 15.7 hours (95%CI 11.1-20.2) in the active treatment period and 42.3 hours 
(95%CI 33.5-51.1) during the placebo treatment (p < 0.001). Number of evacuations per day increased during the use of 
active tea; significant differences were observed as of the second day of treatment (p < 0.001). Patient perception of 
bowel function was improved (p < 0.01), but quality of life did not show significant differences among the study 
periods. Except for a small reduction in serum potassium levels during the active treatment, no significant differences 
were observed in terms of adverse effects throughout the study period.
Conclusions: The findings of this randomized controlled trial allow to conclude that the phytotherapic compound 
assessed has laxative efficacy and is a safe alternative option for the treatment of constipation.
Trial registration: ClinicalTrial.gov NCT00872430
Background
The phytotherapic product assessed in the present study
contains fruits of Pimpinella anisum L. (green anises),
fruits of Foeniculum vulgare Miller (fennel), flowers of
Sambucus nigra L. (sabugueiro), and flowers of Cassia
augustifolia (senna plant). Although this combination has
been commercially available in Brazil since 1926 [1], its
efficacy and safety has never been assessed in a random-
ized clinical trial.
Pimpinella anisum has as chemical representative,
namely the anise oil (1-4%). The major component of
anise oil, trans-anethole (75-90%), is responsible for its
characteristic taste and smell, as well as for its medicinal
properties [2,3]. Other constituents include coumarins
(umbelliferone, umbelliprenine, bergapten, and scopole-
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tin), lipids (fatty acids, beta-amyrin, stigmasterol and its
salts), flavonoids (flavonol, flavone, glycosides, rutin,
isoorientin, and isovitexin), protein and carbohydrate [2].
Anise is well known as a carminative and an expectorant,
and it is also used to decrease bloating, especially in pedi-
atric patients. At higher doses, it is used as an antispas-
modic and antiseptic [2,3], and in vitro studies have also
reported on antimicrobial properties of anise [2].
Foeniculum vulgare contains essential oils (2-6%) com-
posed of up to 50-70% of trans-anethole and up to 20% of
fenchona, in addition to small amounts of limonene,
camphor, and alfa-pinene. The fruits and leaves of Foenic-
ulum vulgare have been shown to contain a number of
flavonoids (quercetin, isoquercetin, kaempferol 3-
glucuronide, and kaempferol 3-arabinoside), fixed oil,
protein, and organic acids [2,3]. Fennel is used as a laxa-
tive in the treatment of mild digestive disorders due to its
gastrointestinal effects, namely stimulation of motility
and, at higher concentrations, antispasmodic action [4].
Administration of fennel seed oil emulsion has been
shown to be superior to placebo in reducing the intensity
of infantile colic in a randomized trial [5].
Sambucus nigra contains essential oils, free fatty acids
(palmitic acid), flavonoids and their glycosides (rutin, iso-
quercitrin, hyperoside and quercitrin), chlorogenic acid,
tannins, and mucilage. It is often used for its laxative
effects [3].
Cassia augustifolia contains anthraquinones (dian-
throne glycosides and sennosides), carbohydrates (poly-
saccharides and mucilage), flavonoids (isorhamnetin and
kaempferol), glycosides (6-hydroxymusizin and tinnevel-
lin), and other constituents. Senna is a potent laxative,
and its use in patients with chronic constipation has been
assessed. However, an increased number of adverse
effects, mainly abdominal pain, have been associated with
senna when compared with other laxatives [2-4].
In spite of the beneficial effects shown in vitro and in
vivo for each of the product components described above,
the effectiveness of the compound has never been
assessed in a randomized clinical trial. In an animal toxic-
ity test, it was considered innocuous in rats and rabbits
even at a dosage 10 times higher than that used in
humans [6].
As an alternative treatment option, phytotherapy may
offer advantages in terms of safety, tolerability, and costs,
improving patient compliance especially in chronic disor-
ders and long-term treatments [7]. A systematic review of
traditional medical therapies for chronic constipation
concluded that there was paucity of data regarding com-
monly used agents such as senna [8]. Another systematic
review carried out in the Cochrane Library on the treat-
ment of constipation in palliative care patients found
inadequate experimental evidence and insufficient data
from randomized controlled trials [9].
Following guidelines of the World Health Organization
on the safety of herbal medicines, the Brazilian Health
Surveillance Agency requires that phytotherapic prod-
ucts be submitted to efficacy and safety evaluation. In this
sense, a randomized clinical trial would provide reliable
d a t a  f o r  e v i d e n c e - b a s e d  d e c i s i o n  m a k i n g  a n d  t h u s
increase the acceptance of phytotherapy among physi-
cians [10].
Therefore, the main objective of the present study was
to evaluate the laxative efficacy of the phytotherapic com-
pound by objective measurement of colonic transit time
(CTT) and clinical variables (number of evacuations per
day and perception of bowel function). Secondary end-
points were the evaluation of safety (adverse effects) and
quality of life.
Methods
Subjects
The target population of the present study comprised
patients with chronic constipation aged 18 to 50 years.
The following criteria were taken into consideration for
the diagnosis of chronic constipation, as defined by the
American Gastroenterology Association (AGA): no crite-
ria for irritable bowel syndrome, no loose stools, and at
least 12 weeks presenting the following conditions (two
or more) in the preceding 12 months: (i) straining in > 1/4
defecations; (ii) lumpy or hard stool in > 1/4 defecations;
(iii) sensation of incomplete evacuation in > 1/4 defeca-
tions; (iv) sensation of anorectal obstruction/blockage in
> 1/4 defecations; (v) manual maneuvers to facilitate def-
ecation in > 1/4 defecations; (vi) < 3 defecations per week
[11,12]. Other inclusion criteria were correct filling of a
constipation questionnaire during the selection phase
and normal laboratory measurements (complete blood
count, serum creatinine and potassium, fasting plasma
glucose, and thyroid-stimulating hormone). Women in
fertile age should be making use of appropriate anticon-
ception. All selected patients signed a written informed
consent form.
The following exclusion criteria were also considered:
current use of medications with known constipating
effects (such as opiates, calcium channel blockers, tricy-
clic antidepressants, and anticholinergic drugs), preg-
nancy or breastfeeding, history of alcohol or drug abuse,
and any other significant or non-controlled disease.
This study complied with good clinical practice stan-
dards, and the study protocol was reviewed and approved
by the Scientific and Ethics Committee of Hospital de
Clínicas de Porto Alegre at Universidade Federal do Rio
Grande do Sul, Porto Alegre, Brazil.
Crossover and washout periods
This was a randomized, placebo-controlled, single-
blinded, crossover study. The order of treatments wasPicon et al. BMC Complementary and Alternative Medicine 2010, 10:17
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counterbalanced across subjects: half of the subjects
received the phytotherapic compound for a 5-day period,
whereas the other half received placebo for the same
period. Both treatment periods were separated by a 9-day
washout period followed by the reverse treatment for
another 5-day period. In the washout period, patients
were free to use any other laxative.
Procedures and data collection
Clinical evaluation, i.e., clinical history and physical
examination, was performed in the beginning and end of
each 5-day period. Laboratory evaluation was carried out
in the beginning of the study and in the end of each study
period. Radiological exams with radiopaque markers
were performed in the end of each phase (placebo and
active tea) to evaluate CTT. The radiologist was blinded
to the intervention.
During the two phases of the study, a constipation
questionnaire assessing intestinal transit, straining, stool
consistency and sensation of fecal obstruction or incom-
plete evacuation in the last 24 hours was filled by patients
on a daily basis. Since there is no validated Portuguese
version of a questionnaire for constipated patients, a new
questionnaire was created with nine questions based on
the AGA criteria and the Bristol Stool Form Scale [13]
(Table 1). We also included a question to assess the
patient's own perception of bowel function, in a scale
ranging from 1 (very poor) to 5 (excellent). In the begin-
ning and end of each phase, quality of life was evaluated
using the WHOQOL-Bref [14], since no specific instru-
m e n t  f o r  q u a l i t y  o f  l i f e  e v a l u a t i o n  i n  c o n s t i p a t i o n  h a s
been validated in Brazilian Portuguese.
Characterization of study substances
According to manufacturer instructions, medicinal plants
Pimpinella anisum, Foeniculum vulgare, and Sambucus
nigra were dried at room temperature and grinded sepa-
rately by a Weg MOI-02 hammer mill. Cassia augustifo-
lia, on the other hand, was submitted to an 8-hour
dehydration process in a recirculation stove at 90°C
before being grinded. Then, the medicinal plants were
homogeneously blended in the following proportion: 2.0
g of Pimpinella anisum fruit (green anises), 2.0 g of
Foeniculum vulgare fruit (fennel), 5.0 g of Sambucus nigra
flower (sabugueiro), and 6.0 g of Cassia augustifolia
flower (senna) to every 15 g of blend. The resulting tea
was finely packed by Laboratórios Klein (Porto Alegre,
Brazil, 2005).
Chemical characterization of the tea was made using
high-performance liquid chromatography (HPLC-UV).
Analysis of the ethanolic extract (80%) was performed on
a Waters 2695 liquid chromatograph equipped with an
autosampler and a Waters UV/vis detector model 2675
controlled by the Empower software (Waters, Milford,
USA). The column was an RP-18 Nova-Pak® 150 × 3.9 mm
i.d., 4 μm particle diameter (Waters, Milford, USA). A
LiChrospher pre-column (10 × 4 mm i.d.) packed with
Bondapak C18 10 μm (Waters, Milford, USA) was
employed. Separation was carried out using a mobile
phase with water: phosphoric acid (100:0.08, v/v) as sol-
vent A and acetonitile (100) as solvent B at a flow rate of
0.6 mL/min. The gradient program was 90-10 B (0 min),
77-23 B (18 min), 0-100 B (25 min), and 0-100 B (30 min).
The system was maintained in equilibrium for 5 minutes
with solvent A before the next injection. The injected vol-
ume was 10 μl. Chromatographic peaks were detected at
256 nm by comparing the retention time with authentic
reference samples of rutin and sennosides A and B. Chro-
matographic separation was achieved at room tempera-
ture.
Interventions
The phytotherapic product was supplied by the manufac-
turer (Laboratórios Klein, Porto Alegre, Brazil) as a
homogeneous mixture of dried botanicals.
Tea was prepared using 15 g of the compound infused
for 5 minutes in 1,500 mL of boiling water. Patients
received 150 mL of active tea (equivalent to 1 g of the
phytotherapic product) or placebo tea three times a day
for 5 days. In order to assure adherence to the study inter-
vention, patient selection was restricted to employees of
the hospital where the study was developed. Patients
were asked to come to the research unit three times a day
to regularly take the tea in front of the investigator. The
pharmacist prepared and administered the tea three
times a day during the trial so that all patients could
receive fresh tea.
Randomization
Patients were randomized to the treatment or the placebo
arm using a single computer-generated random list of
numbers. Only the pharmacist was not blinded to patient
allocation.
Blinding
The research pharmacist in charge of preparing and
administering both teas (active and placebo) did not par-
ticipate in data collection and did not have any other
interaction with patients and investigators. In order to
produce a placebo tea with similar taste and color, 7
drops of caramel color and 10 drops of orange essence
were added to 1,600 mL of boiling water. Patients might
have recognized which tea was placebo and which was
active tea; for this reason, we conservatively considered
this trial to be single-blinded. However, both the clinician
and the radiologist who measured the primary endpoint
and applied the questionnaire were blinded to the inter-
vention during the entire trial.Picon et al. BMC Complementary and Alternative Medicine 2010, 10:17
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Outcomes
Primary outcome was CTT, measured through a radio-
logical technique in which patients were given capsules
prepared by a pharmacist, containing 20 radiopaque
markers, for three consecutive days. Forty eight hours
after ingestion of the last capsule (day 5 and day 19), an
abdominal X ray was performed and the number of
markers still present in the colon was counted. For deter-
mination of the CTT (measured in hours), the following
formula was employed: CTT = 1.2 × NMXr, where NMXr
is the number of radiological markers found in the
abdominal X ray and 1.2 is a constant used by Metcalf et
al. [15].
Secondary endpoints were daily symptoms as informed
in the constipation questionnaire, quality of life, and inci-
dence of adverse events. Any new symptoms or physical/
laboratory abnormalities potentially related with the use
of the product were considered as adverse effects by the
assisting doctor. The use of other laxatives during the
washout period was also measured as a secondary out-
come.
Table 1: Constipation questionnaire and baseline characteristics (n = 20; 19 female)
Question Answer (%)
Q1. Have you evacuated in the last 24 
hours?
Yes 45
No 55
Q2. What is the usual consistency of your 
feces?*
Type 1-3 55
Type 4 15
Type 5-7 25
Missing 5
Q3. Have you made any straining when 
trying to evacuate in the last 24 hours?
Yes 75
No 20
Missing 5
Q4. What was the level of straining in the 
last 24 hours?†
Severe 38
Moderate 44
Mild 13
Missing 6
Q5. Do you have any history of anorectal 
obstruction?
Yes 15
No 85
Q6. Do you have any history of incomplete 
evacuation?
Yes 95
No 5
Q7. Do you have any history of abdominal 
discomfort?
Yes 100
Q8. Do you think you have spent too much 
time trying to evacuate in the last 24 
hours?
Yes 20
No 80
Q9. How do you define your bowel 
function?
Very bad 20
Bad 65
More or less 10
Good 5
* Bristol Stool Form Scale. † Not applicable for 4 patients (Q3 = No) (n = 16).Picon et al. BMC Complementary and Alternative Medicine 2010, 10:17
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Sample size calculation
Sample size was calculated by estimating that a 20-hour
difference in mean CTT would be found between placebo
and active tea at the end of the study. Using data from a
Brazilian sample of constipated patients were mean CTT
(± standard deviation) was 113.1 ± 23.1 hours [16], with a
power (1-β) of 80% and an alpha error of 0.05, the mini-
mum number of patients required to detect a statistically
significant difference was 22 in each period.
Statistical analysis
A l l  a n a l y s e s  w e r e  b a s e d  o n  i n t e n t i o n  t o  t r e a t .  F i s h e r ' s
exact test was used for the comparison of rates and pro-
portions. A paired sample t test was used for continuous
variables at a one-point comparison. For repeated mea-
sures, linear regression analysis was used for intra- and
inter-group comparisons. Wilcoxon signed-rank test and
Friedman test were used to compare the number of evac-
uations per day (measured as intervals). Statistical signifi-
cance was set at 5%.
Study termination
An interim analysis determined a priori, performed with
20 patients (40 measurements) by an independent inves-
tigator, revealed the presence of statistically significant
results, thus leading to early termination of the study.
Results
A total of 20 patients fulfilled the inclusion criteria. Base-
line characteristics of the sample are shown in Tables 1
and 2. Clinical variables such as arterial blood pressure,
heart frequency, and laboratory data did not show signifi-
cant changes during the study. Results obtained in the
constipation questionnaire applied at baseline are shown
in Table 1. Given the cross-over design of the study, each
patient served as his/her own control, thus reducing the
influence of variables such as physical activity, body mass
index or dietary habits upon the outcome.
Efficacy analysis
Mean CTT assessed by X ray was 15.7 hours (95%CI
11.1-20.2) and 42.3 hours (95%CI 33.5-51.1) (p < 0.001) at
the end of the treatment periods with active and placebo
teas, respectively (Figure 1). The mean difference of 26.6
hours (95%CI 18.7-34.6) between active tea and placebo
represented a 62.9% improvement in CTT favoring the
active tea during the 5-day assessment period, well
beyond the expected during sample size calculation. The
magnitude of this difference determined early study ter-
mination after an interim analysis.
As to the subjective analysis, particularly of note was
the question "How many times have you evacuated in the
last 24 hours?": during the placebo treatment, 42% of the
patients answered "none," whereas during the active
treatment, only 14% gave the same answer (Fisher's exact
test, p < 0.001). A comparison of the number of evacua-
tions per day during the study period as informed in the
questionnaire revealed significant differences among
groups as of the second day of treatment (Wilcoxon
signed-rank test) (Figure 2).
The question regarding perception of bowel function
revealed a significant improvement in the active treat-
ment period (intragroup linearity test, p = 0.01). During
the placebo period, on the other hand, there were no sig-
nificant changes in that classification (intragroup linear-
ity test, p = 0.09). At the end of the fifth day of treatment,
a small difference among the groups could be observed
(paired sample t test, p = 0.03) (Figure 3).
During the washout period, four patients reported the
use of laxatives after receiving placebo, and five patients
after receiving the active tea. No significant difference
Table 2: Age, blood pressure, body mass index (BMI), and laboratory assessment of patients (n = 20; 19 female)
Data Mean Min. Max. SD
Age 38.9 25 54 7.49
Systolic blood pressure 
(mmHg)
120.8 96 140 13.89
Diastolic blood pressure 
(mmHg)
77.2 60 100 9.72
BMI (kg/m2) 26.1 18.8 39 4.5
Thyroid-stimulating 
hormone (μUI/mL)
1.49 0.50 2.80 0.65
Serum creatinine (mg/dL) 0.68 0.5 1.0 0.12
Fasting glucose (mg/dL) 91 78 99 5.80
Serum potassium (mEq/L) 4.50 4.0 4.9 0.25Picon et al. BMC Complementary and Alternative Medicine 2010, 10:17
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was detected in the use of laxatives during the washout
period (Fisher's exact test, p = 1.00).
Safety analysis
Quality of life, evaluated with the WHOQOL-Bref ques-
tionnaire, did not show significant differences between
the two study periods (t test, p = 0.2). A small reduction
in mean heart rate was observed during the active treat-
ment period (from 78 in the placebo phase to 70 in the tea
phase; p < 0.001), a difference that may be explained by
stimulation of the vagus nerve as a result of intestinal
cramps.
Some laboratory exams showed statistically significant
differences between the groups, however of no clinical
relevance, once all results remained within normal
ranges. The only significant difference detected was a
decrease in serum potassium (from 4.50 mEq/L to 3.96
mEq/L; p < 0.001) (Figure 4). No severe adverse effects
(e.g. death or risk/disabling events requiring hospitaliza-
Figure 1 Colonic transit time according to treatment periods assessed by X ray. Points represent individual patient values and bars represent 
mean colonic transit times (in hours). Mean difference between active tea and placebo: 26.6 hours (95%CI 18.7-34.6) favoring active tea.
Figure 2 Proportion of one or more evacuations/day according 
to treatment period (active tea vs. placebo).Picon et al. BMC Complementary and Alternative Medicine 2010, 10:17
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tion or leading to study withdrawal) were observed
throughout the study period.
Discussion
The tea prepared with the phytotherapic compound
assessed in the present study presented significant laxa-
tive effects when compared with placebo. This effect was
demonstrated by a decrease in CTT, as well as an increase
in the number of daily evacuations. A few patients also
presented diarrhea and colic while on treatment with the
active tea.
T h e  a d d i t i o n  o f  h e r bs  s u c h  as  f e n n e l  t o  t h is  t ype  o f
compound is a traditional strategy to minimize the
cramping caused by senna and Sambucus nigra. Fennel
may thus be the ingredient responsible for the control of
intestinal colic in our patients.
Phytotherapy is a good alternative treatment for consti-
pation as it may offer a few advantages in relation to other
treatment approaches, e.g. in terms of safety, costs, and
improved patient compliance over a long-term treatment.
However, there is currently a paucity of data regarding
commonly used agents, such as senna [8]. The present
randomized clinical trial was carefully designed and con-
ducted, and therefore we believe it can be used as a reli-
able source for evidence-based decision making.
In our study, previous use of laxatives was not an exclu-
sion criterion, because it would be very difficult to find
treatment-naive constipated patients. Due to ethical rea-
sons, our patients were free to use any other laxative dur-
ing the washout period. Moreover, the Research and
Ethics Committee that approved the study protocol pon-
dered that 14 days (for patients allocated first to placebo)
would be too much time without treatment. Fortunately,
Figure 3 Bowel function perception by patients according to treatment period (active tea or placebo). Values presented as means ± standard 
deviation.
Figure 4 Serum potassium: individual data and mean values ac-
cording to treatment period.Picon et al. BMC Complementary and Alternative Medicine 2010, 10:17
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the use of laxatives during the washout period was not a
bias, since no significant differences were observed in the
frequency of their use after each of the study periods.
A small decrease in potassium serum levels (within
normal ranges) suggests the need for dose titration in
patients at risk for hypokalemia, such as users of diuret-
ics. This finding may be explained by the diarrhea experi-
enced by two of the volunteers during treatment with the
active phytotherapic tea. Nevertheless, dose titration
according to therapeutic effect is probably enough to
control this adverse effect.
The radiological investigation of CTT is not regularly
adopted in the clinical setting. However, our study
showed that this is a very objective way of measuring the
final effect of a laxative. The use of clinical information
provided by the patient in the research setting is useful
but frequently biased by the patient's subjective percep-
tion of the treatment. Both methods may have flaws and
may not reflect real improvement of colonic function.
However, the combination of clinical variables and CTT
assessment, as used in this trial, allowed to obtain a more
precise and accurate evaluation of bowel function.
No change in quality of life was observed; this may be
explained by the short duration of the study and also by
the fact that WHOQOL-Bref is a generic instrument for
the assessment of quality of life, thus not sensitive enough
to evaluate this specific clinical situation.
Conclusions
This is the first randomized controlled trial to demon-
strate the safety and laxative efficacy of a phytotherapic
tea containing Pimpinella anisum,  Foeniculum vulgare,
Sambucus nigra, and Cassia augustifolia. Considering the
high costs and compliance problems of long-term treat-
ments currently available for chronic diseases such as
constipation, this compound comes up as an alternative
treatment approach that would be most welcome by doc-
tors and patients.
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